Antares Pharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Antares Pharma Inc (ATRS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Antares Pharma Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 183M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-9.4% annualized vs trailing 12 months).
- Peer revenue share: Antares Pharma Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ATRS Sales vs. its Competitors, Q1 2022
Antares Pharma Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Medical Equipment & Supplies industry grew revenue 14.5% year over year, combined, vs -1.3% for Antares Pharma Inc. Antares Pharma Inc's share of combined industry revenue moved from 0.04% to 0.04%, a loss of 0.01 percentage points.
Antares Pharma Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Antares Pharma Inc | Yes | Yes | Yes | No |
| High-Confidence Competitors (12) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ATRS Stock Performance relative to its Competitors
ATRS Stock Performance relative to High-Confidence Competitors
ATRS Stock Performance relative to Similar Growth & Profitability Competitors
Antares Pharma Inc's Competitors Named by the Company
Competitive relationships identified from Antares Pharma Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| AbbVie | Company report | 85% |
| Endo | Company report | 85% |
| Scandinavian Health Ltd. | Company report | 85% |
| Viatris | Company report | 85% |
| Owen Mumford Ltd. | Company report | 85% |
| Superior Group Of Companies Inc | Company report | 85% |
| Alteogen Inc. | Company report | 85% |
| Lilly | Company report | 85% |
| Teva | Company report | 85% |
| West Pharmaceutical | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Perrigo | Company report | 85% |
| Stran and Company Inc | Company report | 85% |
| Amphastar Pharmaceuticals, Inc. | Company report | 85% |
| Marius Pharmaceuticals | Company report | 85% |
| Ypsomed AG | Company report | 85% |
| Eli Lilly | Company report | 85% |
| Verity Pharma | Company report | 85% |
| Tolmar | Company report | 85% |
| Bausch Health Companies, Inc. | Company report | 85% |
| Valeant Pharmaceuticals International, Inc. | Company report | 85% |
Company report basis, confidence, active dates and source counts for Antares Pharma Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.